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Mesenchymal Stem Cell Alterations in Bone Marrow Lesions in
Patients With Hip Osteoarthritis
T. Mark Campbell,1 Sarah M. Churchman,2 Alejandro Gomez,2 Dennis McGonagle,2
Philip G. Conaghan,2 Frederique Ponchel,2 and Elena Jones2
Objective. In patients with osteoarthritis (OA),
bone marrow lesions (BMLs) are intimately linked to
disease progression. We hypothesized that aberrant
multipotential stromal cell (also known as mesenchy-
mal stem cell [MSC]) responses within bone tissue con-
tributes to BML pathophysiology. The aim of this study
was to investigate BML and non-BML native subchon-
dral bone MSCs for numeric, topographic, in vitro func-
tional, and gene expression differences.
Methods. Ex vivo 3T magnetic resonance imaging
(MRI) of the femoral heads of 20 patients with hip OA was
performed. MRI-determined BML and non-BML regions
were excised and enzymatically treated to extract cells and
quantify MSCs using flow cytometry and colony-forming
unit–fibroblast (CFU-F) assay. Immunohistochemical
analysis was performed to determine in vivo CD2711
MSC distribution. Culture-expanded CD2711 cells were
analyzed for tripotentiality and gene expression.
Results. BML regions were associated with
greater trabecular bone area and cartilage damage
compared with non-BML regions. The proportion of
CD452CD2711 MSCs was higher in BML regions
compared with non-BML regions (median difference
5.6-fold; P < 0.001); the CFU-F assay showed a similar
trend (median difference 4.3-fold; P5 0.013). Immuno-
histochemistry revealed CD2711 cell accumulation in
bone adjacent to cartilage defects and areas of osteo-
chondral angiogenesis. BML MSCs had lower prolifera-
tion and mineralization capacities in vitro and altered
expression of TNFSF11/RANKL and CXCR4/stromal
cell–derived factor 1 receptor. OA MSCs showed up-
regulated transcripts for CXCR1 and CCR6 compared
with MSCs derived from healthy or osteoporotic bone.
Conclusion. This study is the first to show
numeric and topographic alterations in native MSCs in
the diseased bone of patients with hip OA. Given the
associated functional perturbation of MSCs, these data
suggest that subchondral bone MSC manipulation may
be an OA treatment target.
Osteoarthritis (OA) is the most common form of
arthritis and a major cause of chronic pain and disability
(1). As the population ages, the projected number of
older adults with OA is expected to increase substantially
in the next 2 decades (1). The pathophysiology of OA is
complex, symptomatic treatment is often ineffective, and
no licensed structure-modifying OA drugs are currently
available. Established OA involves pathology in multiple
tissues, but subchondral bone plays an important role in
pathogenesis and symptomatology (2,3).
With the use of magnetic resonance imaging
(MRI), subchondral bone pathology, including bone
marrow lesions (BMLs) (3–6), can be visualized on
fluid-sensitive MRI sequences. Such BMLs are associat-
ed with overlying cartilage pathology, pain, and pro-
gression of structural abnormalities over time (5,7).
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Histologically, BMLs represent mesenchymal tissue
abnormalities including bone marrow fibrosis, necrosis,
swollen/dying adipocytes, and alterations in trabecular
bone structure (7).
Multipotential stromal cells (also known as mes-
enchymal stem cells [MSCs]) are nonhematopoietic,
clonogenic, multipotential cells that are present in
numerous tissues (8). They have attracted great interest
because of their regenerative and immunoregulatory
properties, as well as their increased use in cell-based
therapies (9). However, MSC behavior in vivo and any
potential contribution to the development of OA
remain poorly understood (10).
MSCs are abundant in trabecular bone, where
they have been observed in both perivascular and bone-
lining locations (11–13). Bone-resident MSCs are
important for bone repair and remodeling by virtue of
being precursors of osteoblasts, which not only form
new bone but also control osteoclast activation by pro-
ducing RANKL and osteoprotegerin (14). Within BMLs,
perturbations in bone MSC function may lead to abnor-
mal bone remodeling, which could affect the overlying
cartilage (3). We therefore hypothesized that subchon-
dral bone MSCs contribute to BML pathophysiology and
compared the numbers, topography, in vitro differentia-
tion capacities, and gene expression profiles of MSCs
extracted from paired BML and non-BML regions from
the same OA-affected femoral head.
PATIENTS AND METHODS
Patients and cells. Patients with primary hip OA who
were scheduled to undergo total hip arthroplasty (THA) were
recruited from the orthopedic unit at Chapel Allerton Hospi-
tal, Leeds. All patients met the American College of Rheuma-
tology criteria for the classification of hip OA (15). Exclusion
criteria included a history of inflammatory arthritis, previous
hip surgery, metastatic cancer, or disorders affecting bone. All
patients gave written informed consent, and the study was
approved by the National Research Ethics Committee York-
shire and Humberside. As a control, trabecular bone was har-
vested from the iliac crest in 9 age-matched patients with
pelvic fracture who were otherwise healthy (median age 57
years, range 39–84 years). Femoral heads were also collected
from 5 patients with osteoporosis (OP) who had a femoral
neck fracture (median age 83 years, range 74–92 years).
Femoral heads from patients with OA or OP were col-
lected immediately after removal during THA and placed in
phosphate buffered saline (PBS) (Invitrogen). Twenty-one
femoral heads from patients with OA (median age 65.3 years,
range 48–83 years) were subjected to MRI, and femoral heads
from 7 patients (median age 71 years, range 43–78 years) were
used as controls in real-time quantitative polymerase chain
reaction (qPCR) and flow cytometry validation experiments.
For MRI, explants were mounted on a nonmetal bracket and
clamp with orienting cut-outs (Figure 1A) and secured in a
PBS-containing polyethylene jar (Figure 1B). Cod liver oil pills
were fixed externally to provide further position markers.
These orienting markers could be visualized on MRI and dur-
ing manual processing. Samples were kept at room tempera-
ture, and MRI was performed within 4 hours of sample
collection.
MR image acquisition and analysis. MR images
were obtained with a Verio 3.0T MRI system (Siemens). MRI
was performed using fat-suppressed, fast spin-echo, proton
density–weighted sequences. T1-weighted sequences were
obtained in 1 plane to identify BMLs (Figure 1C). To ensure
accurate cutting measurements in 3 dimensions for separation
of BML from non-BML regions, MRI sequences were
Figure 1. Segregation of bone marrow lesion (BML) and non-BML
regions and downstream processing. A, Femoral head in plastic
bracket. B, Femoral head/bracket in a phosphate buffered saline–
containing polypropylene jar. C, Proton density–weighted sequence
magnetic resonance images in 3 planes, with measurements for cuts
(top and bottom left) and corresponding T1-weighted sequence
image obtained in the “coronal” plane (bottom right). D, Bone
segregation apparatus. E, BML bone fragments used for collagenase
treatment after mincing with a rongeur.
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obtained in 3 planes (axial, coronal, and sagittal) (Figure 1C).
BMLs were defined as areas of increased signal intensity
adjacent to subcortical bone on proton density–weighted
sequences that had low intensity on T1-weighted sequences
(Figure 1C). For additional information, including MRI
sequence settings, see Supplementary Table 1 (available on
the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39622/abstract).
MR images were examined using Siemens syngo fast-
View software for DICOM images. Identification of BML and
non-BML regions was first performed by a physiatrist with
experience in musculoskeletal imaging (TMC). Interpretation
was repeated independently by a radiologist with expertise in
musculoskeletal imaging (RH), with blinding with regard to all
patient data and prior interpretation. Consensus regarding
BML and non-BML regions was then reached by discussion.
Because the patients recruited into the study had severe OA,
we acknowledge that non-BML regions are unlikely to repre-
sent “normal bone”; however, the most normal-appearing
bone was selected.
Excision of specimens from BML and non-BML
regions, and downstream tissue processing. MRI measure-
ments were performed in all 3 proton density–weighted
sequence planes (Figure 1C). Bone cutting measurements
were planned using the measuring tool of the image visualiza-
tion software. Measurements and sample orientation were
accomplished with reference to sample anatomic landmarks
(e.g., outer cortex apex, ligamentum teres, osteophytes). A
sterile marker was used to mark orienting lines on the sample
corresponding to the anteroposterior and mediolateral land-
marks on the bracket, so that orientation was maintained.
All bone processing was performed in a tissue culture
hood, using sterile technique. After the femoral heads were
removed from the bracket, they were placed in a vice, and the
remainder of the femoral neck was used to hold the sample to
prevent damage to the subchondral regions (Figure 1D). BML
Figure 2. Histologic appearance of bone and cartilage in bone marrow lesion (BML) and non-BML specimens. A and B,Gross histologic appearance
of an excised BML specimen with a subchondral cyst (arrow) (A) and corresponding non-BML specimen from the same femoral head (B).C,Compar-
ison of trabecular bone area (BML versus non-BML) as a percentage of the total area (n5 14 pairs). *5P5 0.001. D and E, Excised BML specimen
showing some cartilage abnormalities above the articular end plate (D) and non-BML fragment from the same femoral head showing intact cartilage
above the articular end plate (E). F and G, Photomicrographs of Safranin O–stained paired BML (F) and non-BML (G) specimens after decalcifica-
tion in EDTA, showing a greater trabecular area in the BML region. Bars5 3.8 mm (A and B), 500 mM (D and E), and 600 mM (F andG).
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and non-BML portions of bone were removed from the femo-
ral head, referencing the 3-dimensional cut plan (Figure 1D).
Because BMLs have an ill-defined border, a 2–3-mm gap was
left between BML and non-BML regions to ensure that BML
bone was well separated from non-BML bone.
Excised pieces of BML and non-BML regions were
each divided into 2 portions: one for histology and one for cell
extraction following enzymatic release (11). Samples prepared
for collagenase treatment were minced using a rongeur
(Figure 1E) and then placed in low-glucose Dulbecco’s modified
Eagle’s medium (DMEM; Life Technologies) with 20% fetal
calf serum (FCS) (Sigma) and animal origin–free collagenase
(3,000 units/gm bone) (Worthington Biochemical Corporation)
for 4 hours at 378C (11). After completion of the collagenase
treatment, a fraction of the cells (average 1.53 105) was obtained
for flow cytometry, and the rest of the cells were frozen in FCS
supplemented with 10% dimethylsulfoxide (Sigma) for later use.
Samples for histologic analysis were placed in 10% formalin
(Sigma) before processing.
Histologic and immunohistochemical analysis. For
each patient, separate BML and non-BML femoral head
pieces were decalcified using 12.5% EDTA (Sigma) in deion-
ized water for 3–4 months and then mounted on paraffin
blocks. Decalcified tissue specimens were stained with hema-
toxylin and eosin or Safranin O, using standard protocols.
Digital image analysis was performed to evaluate relative
trabecular bone area and cartilage damage. For each sample, the
whole tissue area was scanned using a Nikon E1000 microscope
under brightfield mode and a multispectral Nuance camera
(PerkinElmer). Using the femoral head cartilage surface to orient
the tissue, the overall section was then separated into cartilage
(including the cartilage–bone interface) and bone. The presence
of cysts in the bone area (Figure 2A) was taken into consideration,
and tissue that was immediately adjacent was not used for quanti-
tative bone area measurements. Depending on the size of the sec-
tion, at least 5 (nonoverlapping) images were captured for the
bone area and 2–5 images were captured for the cartilage area.
Nuance version 3.0.1.2 software (Caliper Life Sciences)
was used for digital image analysis. Educating the software to rec-
ognize trabecular bone was done by manually determining small
representative areas of bone and repeating the process until
.95% accuracy in identifying bone was achieved automatically.
For each tissue section, the full area was measured, and the tra-
becular bone area was calculated as a percentage (mean6 SD of
a minimum of 5 images). For cartilage assessment, 10 positions
were spaced out over the length of available cartilage in each
image and repeated over 2–5 images (depending on the size of
the tissue). Cartilage appearance was classified as “less dam-
aged” or “more damaged” based on superficial zone smoothness,
clefts, fibrillation, and presence of sclerotic bone or reparative tis-
sue within denuded surface (16) (Figures 2D and E).
Immunohistochemistry for CD271 staining was per-
formed as optimized by Tormin et al (12). Mouse anti-human
CD271 monoclonal antibody (Abcam) was used at a dilution
of 1:50. (For a complete list of reagents, see Supplementary
Table 2, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.39622/abstract).
Flow cytometry. For MSC enumeration, flow cytom-
etry was performed on freshly enzymatically treated samples
using a BD LSRII flow cytometer (BD Biosciences).
Depending on the cellularity of collagenase-treated samples,
;1–2 3 105 cells were resuspended in 50 ml of fluorescence-
activated cell sorting (FACS) buffer (PBS plus 0.5% bovine
serum albumin) and incubated in a 10% Fc receptor–block-
Figure 3. Mesenchymal stromal cell (MSC) enumeration in fractions of
cells released from bone marrow lesion (BML) and non-BML regions, fol-
lowing collagenase treatment. A, Representative flow cytometry plots for
CD452CD2711 MSC populations showing a rectangular selection for
MSC enumeration. B, Paired-sample line graphs showing CD452
CD2711 MSCs as a percentage of total live cells (left) and CD901 cells
as a percentage of CD452CD2711 cells (right) in BML versus non-BML
cell fractions (n5 20 each). C, Left, Dot plots from a BML sample with
gating on the CD451 lymphocyte population. Right, Paired-sample line
graphs showing lymphocytes as a percentage of total live cells in BML
versus non-BML cell fractions (n5 20 each). D, Colony-forming unit–
fibroblast (CFU-F) assay. Left, Representative 25-cm2 flasks. Right,
Paired-sample line graph showing the number of CFU-Fs per 106 plated
cells in BML and non-BML regions (n5 14 each). In all line graphs, bars
show the median. *5P, 0.05; ***5P, 0.001.
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ing reagent solution (Miltenyi Biotec) before fluorophore-
conjugated antibodies were added. Staining was performed
for CD90, CD73, CD45, and CD271 (for additional informa-
tion, see Supplementary Table 3, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.39622/abstract), and dead cells were excluded
using live cell marker calcein violet and dead cell marker
aqua-fluorescent reactive dye (Invitrogen) (17). The propor-
tion of MSCs gated as CD452CD2711 cells (11,12) was cal-
culated relative to total live cells (Figure 3A). MSC extended
phenotype was investigated using CD73 and CD90 markers.
The percentages of lymphocytes (18) were similarly calculat-
ed relative to the total number of live cells.
The MSC identity of BML- and non-BML–derived
adherent cultures was investigated following staining with a
standard panel of antibodies defining the phenotype of cul-
tured MSCs (19). Passage 3 cultures grown from BML- and
non-BML CD271–selected cells were trypsinized and resus-
pended at 107 cells/ml in FACS buffer. Antibody combinations
included the following: phycoerythrin–Cy7 (PE–Cy7)–
conjugated CD45, PerCP-conjugated CD34, allophycocyanin
(APC)–conjugated CD271, APC-H7–conjugated CD14, and
fluorescein isothiocyanate (FITC)–conjugated CD19 and PE-
labeled antibodies, including PE-conjugated CD73 (ecto-50-
nucleotidase), PE-conjugated CD105 (endoglin), and PE-
conjugated CD90 (Thy-1) (for additional information, see
Supplementary Table 3). All antibodies were used at the con-
centrations recommended by the manufacturers, with matched
isotype controls. Dead/dying cells (normally ,5% of total
cells) were excluded from the analysis using 10 ml/ml DAPI
(Sigma). All flow cytometry data were analyzed using Diva
version 6.2 software (BD Biosciences).
Colony-forming unit–fibroblast (CFU-F) assay and
MSC expansion from BML and non-BML collagenase
digests. A CFU-F assay was performed as described previous-
ly (11), with a minor modification using methylene blue,
before scoring was performed in a blinded manner. MSC
expansion was used to measure MSC proliferation rates and to
produce a sufficient number of cells for trilineage differentia-
tion assays and gene expression analysis. MSCs were expanded
in StemMACS MSC Expansion Media after preenrichment
using CD271 MACSelect MicroBeads (both from Miltenyi
Biotec), and culture population doublings were calculated as
previously described (20). MSCs from the bone of healthy con-
trols and patients with OP were expanded similarly following
their enzymatic release from bone (11).
Trilineage differentiation. Passage 2/3 MSCs (n5 5
matched donor–derived cultures for BML and non-BML bone
tissue digests) were induced toward osteogenesis, chondrogen-
esis, and adipogenesis, using standard protocols (21). For oste-
ogenesis and chondrogenesis, we used StemMACS OsteoDiff
and ChondroDiff medium, respectively (Miltenyi Biotec); adi-
pogenic cultures were grown in DMEM with 10% FCS, antibi-
otics, 10% horse serum (StemCell Technologies), 0.5 mM
isobutylmethylxanthine, 60 mM indomethacin, and 0.5 mM
hydrocortisone (all from Sigma).
Differentiation assessment was performed as previously
described (21). Briefly, alkaline phosphatase activity was
visualized on day 14 postinduction. Calcium deposits were
stained using alizarin red on day 21, and total calcium produced
by cultures was measured using a Calcium Detection Kit (Senti-
nel Diagnostics). Biochemical assessment of the glycosamino-
glycans (GAGs) was performed on 3 of 4 chondrogenic pellets
grown for 21 days. The remaining pellet was used for histologic
analysis; 4-mm sections were cut using a Leica CM1950 cryostat,
fixed, and stained with toluidine blue. Adipogenic cultures were
stained with oil red O on day 21 postinduction.
Real-time qPCR. To investigate MSC molecular pro-
files, paired CD271 bead–selected BML and non-BML pas-
sage 2 cultures were analyzed for their relative expression of
genes involved in MSC tripotentiality, collagen metabolism,
chemotaxis, angiogenesis, and control of osteoclast activation.
Other selected genes included those previously described as
being associated with OA (3,22) (see also Supplementary
Table 4, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.39622/abstract).
MSCs derived from trabecular bone from age-matched con-
trols as well as MSCs derived from the femoral heads of
patients with OP were included as controls.
Reverse transcription and qPCR were performed
using a custom Format 48 TaqMan low-density array (Life
Technologies) (see Supplementary Table 4), as previously
described (20). Mean fold changes were calculated and were
considered further if the change was $2-fold. Selected tran-
scripts were validated on additional samples using individual
TaqMan assays, matching those included in the TaqMan low-
density array. Tests were performed in triplicate on 5 ng com-
plementary DNA per well.
Statistical analysis. Differences between paired BML
and non-BML samples for trabecular bone area, flow cytometric
measurements of MSC and lymphocyte proportions, CFU-F
assays, MSC growth, gene expression, and differentiation data
were compared using the 2-sample paired sign test. Gene expres-
sion differences using control MSC cultures (3 groups: OA,
healthy control, and OP MSCs) were tested by Kruskal-Wallis
test with Dunn’s multiple comparison tests. The chi-square test
was used to establish associations between cartilage appearance
(less damaged versus more damaged) and BML/non-BML
images. P values less than or equal to 0.05 were considered sig-
nificant. All tests were performed using IBM SPSS Statistics 21.
RESULTS
Subject recruitment. Twenty-one patients were
considered for recruitment into the ex vivo MRI study,
but 1 of the patients showed no detectable BMLs
on MRI and was excluded. Half of the patients were
women, and all were white. The median age was 65.3
years (range 48–83 years), and the median body mass
index was 28.4 kg/m2 (range 20.7–42.8). Half of the
patients were receiving nonsteroidal antiinflammatory
drugs, and none were receiving bisphosphonates.
Twenty-five percent of the patients were smokers, and
85% had Kellgren/Lawrence grade 4 hip OA (23).
Histologic features segregating BML from non-
BML regions. To confirm the accuracy of our BML
sampling, we performed histologic assessment of bone
and cartilage in paired BML and non-BML samples
from 14 randomly selected patients. BMLs have been
1652 CAMPBELL ET AL
characterized by a high bone volume fraction (24). For
trabecular area analysis, 320 images of bone were
acquired: 198 images for BML samples (average of 9.3
images per sample [range 5–14]) and 122 images for
non-BML samples (average of 6.6 images per sample
[range 5–9]). The average trabecular bone area per sam-
ple (n5 14 pairs) was widely distributed between the
patients; however, a clearly higher trabecular area was
observed in BML compared with paired non-BML sam-
ples (P5 0.001) (Figures 2C, F, and G).
BMLs were also associated with overlying carti-
lage defects (25,26). Cartilage assessment was per-
formed in the group of samples from 14 donors.
Following decalcification, 9 of 14 paired tissue samples
had sufficient amounts/quality of cartilage to enable
paired analysis, and 74 images were acquired for the
cartilage region: 43 BML (average of 5 images per sam-
ple [range 2–9]) and 31 non-BML (average of 3 images
per sample [range 2–14]). Images showing more dam-
aged cartilage (assessed by comparing the relative
smoothness of cartilage, presence of clefts, fibrillation,
and sclerotic bone or reparative tissue within denuded
surface [16]) were closely associated with BML samples
(24 of 43 images) compared with non-BML samples (5
of 31 images; P5 0.01), where most of the cartilage sur-
face was considered to be less damaged (Figures 2D and
E). Taken together, these findings were consistent with
the expected histologic features of BML and non-BML
regions, confirming the accuracy of the excision method.
MSC enumeration by flow cytometry and CFU-F
assay. Representative flow cytometry plots for CD452
CD2711 MSC populations are shown in Figure 3A.
Despite broad donor-to-donor variation, a greater pro-
portion of CD452CD2711 cells as a percentage of total
live cells was observed in BML compared with non-BML
tissue digests (median difference 5.6-fold; P, 0.001) (Fig-
ure 3B). The expression of 2 additional markers (CD73
and CD90) was also assessed on CD452CD2711 cells to
confirm their MSC identity. In both BML and non-BML
regions,.85% of CD452CD2711 cells were CD731 (for
BML, mean 87.5%; for non-BML, mean 89.5% [P5not
significant]). The CD452CD2711CD901 cell subpopula-
tion, a recently described phenotype of the most clono-
genicMSCs (27), was also higher in BML regions (median
1.7-fold; P5 0.041) (Figure 3B). In contrast to the
observed differences in MSC numbers, no difference in
the percentages of lymphocytes (gated as CD45brightSSClow
cells [18]) in BML and non-BML digests was observed
(P5 0.824) (Figure 3C). To further validate this difference
in MSC frequency, a CFU-F assay was performed in 14
pairs of tissue digests, and the same trend was observed
(median difference 4.3-fold; P5 0.013) (Figure 3D).
Topography of CD2711 MSCs in excised BML
and non-BML specimens. We next performed immu-
nohistochemical analysis to investigate the localization
of CD2711 cells within the excised samples. In both
Figure 4. CD271 cell distribution in light microscopy images of
bone marrow lesion (BML) and non-BML specimens as assessed by
immunohistochemistry. A and B, Perivascular distribution in repre-
sentative negative control (A) and CD271-stained (B) non-BML
specimens. C, Representative non-BML specimen showing CD271
staining in bone lining. D, CD2711 staining near osteochondral
junction and surrounding a bone cyst (BC) in a representative BML
sample. E, Higher-magnification view of boxed area in D, showing
CD2711 staining within the subarticular end plate immediately
beneath a chondral lesion (arrows). F, High-magnification view of
BML sample, showing subchondral CD2711 perivascular staining
(arrowheads) and CD2711 staining within subarticular end plate
immediately beneath chondral lesion (arrow). G, Non-BML sample,
showing relatively intact cartilage and lacking CD271 expression.
Bars5 100 mm (A–C), 3 mm (D), 400 mm (E and F), and 200 mm (G).
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BML and non-BML tissues, CD271 staining was distrib-
uted as expected in a perivascular and reticular pattern
in marrow cavities (Figure 4B) (12,13). Additionally,
CD271 positivity was clearly detectable in bone lining
locations (Figure 4C).
A highly heterogeneous distribution of CD271
positivity (due to the large intersubject heterogeneity of
bone pathology and cartilage OA architectural changes)
did not allow reliable quantification of CD2711 cells
using digital imaging analysis to directly compare
excised non-BML and BML specimens. However, in the
BML samples, accumulation of CD271 staining was par-
ticularly evident in the regions adjacent to subchondral
bone cysts (Figure 4D) and cartilage damage (Figures
4D–F) at osteochondral junctions where overlying carti-
lage loss was more pronounced. In addition to perivas-
cular staining (Figure 4F), there was substantial staining
of fibrous stromal tissue extending toward and up to the
cement line from the subchondral bone (Figures E and
F), suggesting that MSCs had accumulated at regions of
cartilage damage. Stained stromal tissue was often seen
invading more damaged cartilage “from below” in
BMLs (see Supplementary Figures 1A and B, available
on the Arthritis & Rheumatology web site at http://online-
library.wiley.com/doi/10.1002/art.39622/abstract); how-
ever, there was no positive CD2711 staining within the
cartilage itself (Figure 4G).
In vitro growth and differentiation capacities of
CD2711 MSC–derived cultures. CD2711 bead–selected
cells from BML and non-BML digests possessed the
standard MSC phenotype following culture expansion
(Figure 5A). To test whether BML-resident CD2711
Figure 5. Surface phenotype, growth rates, and differentiation capacities of CD271 cell–derived cultures from bone marrow lesions (BMLs) and
non-BMLs. A, Flow cytometry histograms showing positive (CD73, CD90, CD105) and negative (CD45) marker expression in BMLs and non-
BMLs from a representative donor. Dashed lines indicate isotype controls. B, Culture growth rates at different passages (for passages 0–2 [P0–
P2], n5 5; for P3, n5 2). Bars show the mean6 SD. C, Adipogenesis in paired BML and non-BML adipogenic cultures. Left, Percentage of oil
red O–positive area versus total cell area in BML and non-BML cultures (n5 5 each). Right, Representative photomicrographs of paired BML
and non-BML cultures at 403 magnification and 2003 magnification (left and right images, respectively). D, Osteogenesis in paired BML and
non-BML osteogenic cultures. Left, Calcium production in BML and non-BML osteogenic cultures (n5 5 each). Right, Representative alkaline
phosphatase (purple) and alizarin red (red) staining of BML and non-BML osteogenic cultures. E, Chondrogenesis in paired BML and non-BML
chondrogenic cultures. Left, Glycosaminoglycan (GAG) production in BML and non-BML chondrogenic cultures (n5 5 each). Right, Gross
images of wet chondrogenic pellets (bars represent 1-mm spacing) and light microscopy images of toluidine blue–stained cartilage pellets at 403
magnification. Data in C–E are shown as box plots, representing the 25th, 50th, and 75th percentiles. *5P, 0.05. PD5 population doubling.
1654 CAMPBELL ET AL
MSCs had altered functional capacities, the growth
kinetics of CD2711 cell cultures were examined. BML
cultures had slightly longer population doubling times
compared with non-BML cultures (P5 0.049 for all pas-
sages combined; n5 5 donors) (Figure 5B).
Regarding their differentiation capabilities, paired
BML and non-BML cultures showed similar levels of
adipogenesis (Figure 5C). No differences were observed
in alkaline phosphatase staining on day 14 postinduction
of osteogenesis (Figure 5D); however, on day 21 postin-
Figure 6. Relative gene expression in CD2711 cell–derived mesenchymal stem cell cultures from bone marrow lesions (BMLs) and non-BMLs
in the bone of patients with osteoarthritis (OA), healthy controls (HCs), and patients with osteoporosis (OP). A, Mean fold changes in relative
gene expression in BML versus non-BML cultures; n5 7 paired samples. The 22DCt value was normalized to the value of HPRT. Black bars indi-
cate P, 0.05 by Wilcoxon’s test for paired data. B, Top, Validation of CXCR4 differential expression as determined by TaqMan quantitative
polymerase chain reaction (qPCR) analysis. Bottom, Validation of RANKL surface protein expression as determined by flow cytometry. C, Vali-
dation of genes putatively specific for OA mesenchymal stem cells (MSCs) using additional OA (n5 7), HC (n5 9), and OP (n5 5) MSC cul-
tures. D, Expression of CXCR4 and TNFSF11 (encoding RANKL) in additional OA, HC, and OP MSC cultures. Gene expression that is
significantly different in OA MSCs compared with both HC MSCs and OP MSCs is indicative of an OA phenotype. The y-axis indicates expres-
sion relative to HPRT. Kruskal-Wallis grouped comparison P values are shown in graphs, with paired significance indicated by P, 0.05 (*) and
P, 0.01 (**). MFI5mean fluorescence intensity; NS5 not significant.
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duction, BML cultures produced lower amounts of calci-
um (P5 0.043) (Figure 5D). No obvious trends were
observed in chondrogenesis assays, assessed either quali-
tatively (chondrogenic pellet staining with toluidine blue)
or quantitatively (GAG assay) (Figure 5E).
Comparative gene expression signatures of
MSCs from BML and non-BML digests. The expres-
sion of 46 genes involved in MSC function, collagen
metabolism, chemotaxis, angiogenesis, and control of
osteoclast activation was measured using qPCR in
CD2711 cell–derived cultured MSCs from OA patients
(n5 7 BML/non-BML pairs). The 2 differentially
expressed bone-related genes between BML and non-
BML cultures (CXCR4 and TNFSF11) (Figure 6A)
were subsequently validated by individual TaqMan
assays and flow cytometry. Consistent with TaqMan
low-density array data, expression of the receptor for
stromal cell–derived factor 1 (SDF-1), CXCR4, was lower
in BMLMSCs, using qPCR (Figure 6B). CXCR4 surface
protein was present only in a small percentage (28) of cells
in all 5 paired BML/non-BML MSC cultures (see Supple-
mentary Figure 2A, available on the Arthritis & Rheumatol-
ogy web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.39622/abstract). The mean fluorescence intensity of the
surface protein RANKL (encoded by TNFSF11) was low-
er in 4 of 5 cultures of BML MSCs compared with non-
BML MSCs, as demonstrated using flow cytometry (Fig-
ure 6B). The remaining genes were not differentially
expressed between BML and non-BML digests.
Comparative gene expression signatures of
MSCs from OA, OP, and healthy bone. To determine
whether differential MSC gene expression in femoral
heads was a feature of hip OA, we compared all OA
MSC transcripts (averaging BML and non-BML Taq-
Man low-density array data for the genes that were not
differentially expressed) with healthy control MSCs
(n5 5) and OP MSCs from femoral heads (n5 3).
When OA MSCs were compared with healthy control
MSCs, significantly different levels were observed for
8 transcripts. Transcript levels for 5 of these transcripts
were higher in OA MSCs: CXCR1/interleukin-8 (IL-8)
receptor a-chain and CCR6/macrophage inflammatory
protein 1a (MIP-1a) receptor (mostly below detection
in healthy control MSCs), GDF5/growth differentiation
factor 5 (8-fold), MMP1/matrix metalloproteinase 1 (23-
fold), and TGFBR2/transforming growth factor b recep-
tor 2 (2-fold). The levels of another 3 transcripts were
lower: ACAN/aggrecan (2-fold), NTRK1/high-affinity
nerve growth factor receptor (10-fold), and NGFR/low-
affinity nerve growth factor receptor (2-fold). We next
used qPCR (Figure 6C) and flow cytometry (see Supple-
mentary Figure 2B, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.39622/abstract) to validate some of these putative
OA-specific genes, using additional cultures of OA MSCs
(n5 7), and compared expression with that in healthy
control MSCs (n5 9). We were mindful that these differ-
ences could be attributable to OA MSCs and healthy con-
trol MSCs having been derived from anatomically
different bones (femoral head versus iliac crest [29]);
therefore, we analyzed OP MSCs (n5 5), which were also
derived from femoral head bone. This analysis confirmed
that expression of CXCR1, CCR6, and GDF5 was signifi-
cantly different across the 3 groups (Figure 6C), and that
CXCR1 and CCR6 were OA-specific (as shown by signifi-
cantly higher expression in OAMSCs compared with both
healthy control MSCs and OP MSCs). CXCR1 surface
protein expression was also higher in OAMSCs compared
with healthy control MSCs and OP MSCs, and shown
using flow cytometry (see Supplementary Figure 2B, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39622/abstract).
Finally, we investigated whether the expression
of CXCR4 and TNFSF11 was OA-specific (Figure 6D).
Using additional OA, healthy control and OP MSC cul-
tures, we observed that CXCR4 expression was signifi-
cantly different across the 3 groups and higher in OA
MSCs compared with healthy control MSCs (Figure
6D). TNFSF11/RANKL expression was variable across
the 3 groups, as demonstrated by the results of qPCR
(Figure 6D) and flow cytometry, respectively (Supple-
mentary Figure 2B).
DISCUSSION
Relatively little is known about the role of endog-
enous MSCs in OA-related bone pathophysiology (10).
Given that MSCs are thought to be master regulators of
joint and bone homeostasis (30), we investigated whether
they might be involved in OA BMLs, which is known to
be associated with both pain and structural changes
(31). To our knowledge, this study is the first to evaluate
native subchondral bone MSCs in human OA in relation
to tissue damage. Our findings show numeric, topo-
graphic, gene expression, and functional perturbations
in MSCs from patients with hip OA, especially from
areas of cartilage loss in BMLs.
Previous studies investigated OA MSCs from
anatomic sites remote from damaged areas, i.e., from
iliac crest bone marrow (32) and from femoral canal
bone marrow (33), both after culture expansion. Our
previous analysis of CD452CD2711 cells sorted from
whole OA femoral heads did not reveal any significant
signs of premature aging or gross osteogenic abnormality
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compared with control bone (11). In the current study,
we carefully excised BML and non-BML areas of a femo-
ral head, as segregated using MRI, and were able to
detect subtle differences in MSC features within the
same affected joint but in relation to the amount of tissue
damage. The histologic features of excised BML and
non-BML regions in our study were consistent with antic-
ipated tissue abnormalities in BMLs, such as an increased
bone volume fraction (24) and overlying cartilage loss
(25,26).
We first showed that MSCs were proportionally
increased in more diseased OA bone; this was initially
surprising but not entirely unexpected considering pre-
viously published reports of the increase in synovial flu-
id MSCs in relation to OA severity (34,35). Consistent
with these findings, Harris et al recently documented
aberrant MSC accumulation in the joints of patients
with advanced OA (36). Additionally, an increase in
subchondral bone MSCs was recently documented in a
mouse anterior cruciate ligament transection model of
OA (37).
In accordance with data from the studies by
Harris et al and Zhen et al and with their proposed
mechanism for increased MSCs in OA joints (36,37), we
observed that the OA MSC chemokine receptor tran-
script profile was consistent with the notion of their
potential recruitment from deeper marrow cavities
toward the joint surface. BML MSCs may indeed be
recruited to more damaged areas of cartilage and super-
ficial subchondral bone due to higher concentrations of
SDF-1 in these regions, which is the result of diffusion
to subchondral bone from OA synovial fluid via thinned,
damaged cartilage (38,39). Our data suggest that once
at the site of damage, MSC CXCR4 expression may be
down-regulated to prevent further migration.
Furthermore, OA MSCs up-regulated CXCR1
(receptor for IL-8) and CCR6 (receptor for MIP-3a), 2
chemokines that are known to be abundant in OA syno-
vial fluid (36,40) and have been shown to be potent
inducers of bone marrow MSC migration (41). There-
fore, both the gene expression data and the immunohis-
tochemical staining pattern, where MSCs were
abundant in regions underlying cartilage defects, sup-
port the notion of their migratory response (42) toward
areas of cartilage loss where the influences of inflamma-
tory synovial fluid chemokine gradients are the stron-
gest. In progressive OA, however, this response appears
to be inadequate, pointing toward the possibility of a
defect in MSC recruitment following skeletal damage.
In the current study, a lower MSC calcium
production capacity of BML MSCs compared with non-
BML MSCs was observed, which could explain histo-
logic findings of reduced tissue mineral density in BML
bone despite a higher cross-sectional bone area. Inap-
propriate mineralization of BML bone could also be
attributable to the defect in the capacity of BML MSCs
to regulate bone remodeling. Compared with non-BML
MSCs, BML MSCs expressed less RANKL surface pro-
tein in 4 of 5 matched MSC cultures tested. Shifts in
RANKL expression, at both the messenger RNA and
protein levels, have been previously documented for
OA subchondral bone osteoblasts and explained by
their “different stages of attempts to repair” (43). This
further supports the concept of “uncoupled” bone for-
mation and resorption by subchondral bone in OA (37),
conceivably altering the biomechanical and load-
distribution properties of OA bone, putting cartilage at
higher risk of injury. Such alterations support the need
for further development of novel therapies targeting
subchondral bone homeostasis for the treatment of OA
(2,44–46). In this context, our findings indicate that the
MSC population is affected by the OA process and may
therefore be an important therapeutic target for modu-
lation in early disease.
Our histologic data showed that in the femoral
heads of patients with OA, CD2711 MSCs surrounded
vessels that had penetrated up to the cement line. MSCs
can indeed act as promoters of angiogenesis (10) and
are closely associated with pericytes and catecholamin-
ergic nerve fibers (13,47). OA neurovascular changes at
the osteochondral junction, including vessels and both
sensory and sympathetic nerves breaching the tidemark,
are now considered to be a possible source of OA joint
pain (48,49). Based on our immunohistochemistry data,
it is not unreasonable to suggest that MSCs in patients
with advanced OA could also take part in pathologic
subchondral neurovascular ingrowth (via their angio-
genic actions and vessel-stabilizing functions) and hence
contribute to the development of joint pain.
This study is limited by the number of OA
patients recruited for the MRI study and the amount of
material that could be distributed to all of the experi-
mental arms. Although the study was sufficiently pow-
ered to detect numeric and functional differences in
paired BML/non-BML MSC populations, some statisti-
cal analyses, such as gene expression validation using
flow cytometry and TaqMan qPCR, were not possible in
all cultures. Although the expression of GDF5, a growth
factor and known OA susceptibility gene (22,50), was
found to be different in OA MSCs compared with
healthy control MSCs and OP MSCs, further work is
required to assess its role in influencing MSC activity at
the site of damage. This is in contrast to our data for
CXCR1 and CCR6, the expression of which was con-
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firmed to be OA-specific. Finally, although we were
able to observe a difference in CD271 immunohisto-
chemical staining distribution between BML and non-
BML samples, tissue architectural heterogeneity pre-
vented us from making a statistical evaluation of these
data and comparing it with our flow cytometry findings.
In summary, our data show that in subchondral
bone from patients with late-stage hip OA, MSCs are
increased in number in the areas of damage but exhibit
functional and gene expression perturbations that could
lead to further damage escalation. In relation to the
development of novel therapy for early OA, our work
emphasizes the abundance of subchondral bone MSCs
in humans and provides initial insight into potential can-
didate pathways that can be targeted in order to normal-
ize or improve the MSC pool. New therapies targeting
the bone–cartilage interface (14) and aimed at reestab-
lishment of a functional cartilage surface zone (10)
could delay progression of the disease, particularly if
they are combined with other interventions such as cor-
rection of joint biomechanics.
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